Cardiac Tumors: Clinical Presentation, Diagnosis, and Management
Cardiac masses and tumors are a heterogenous group of disorders and include primary tumors (both benign and malignant), metastatic disease, and numerous masquerades such as thrombus. Clinical presentation ranges from incidental discovery on imaging tests ordered for other reasons to life-threatening presentations such as cardiac tamponade, arrhythmia, obstruction, and systemic embolization. Of the available imaging modalities, cardiac MRI is generally the most useful for assessment and helps to delineate the relevant anatomy. Due to the technical difficulties and risk of biopsy of cardiac masses, a presumptive diagnosis is typically made using imaging techniques with surgery serving both a diagnostic and curative role. Because these conditions can vary widely in their management, we recommend early involvement of a multidisciplinary group which should include a cardiologist, cardiac surgeon, and oncologist.
KeywordsCardiac mass Cardiac tumor Myxoma Rhabdomyoma Rhabdomyosarcoma
Compliance with Ethical Standards
Conflict of Interest
Timothy J. Poterucha owns a stock in Abbott Laboratories and AbbVie, Inc.
Jonathan Kochav declares that he has no conflict of interest.
Daniel S. O’Connor declares that he has no conflict of interest.
Gregg F. Rosner declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.Primary tumors of the heart. In Bonow RO, Mann DL, Zipes DP, Libby P (eds): Braunwald’s heart disease. 9th ed. Philadelphia, Elsevier Saunders, 2011, pp 1638–1650.Google Scholar
- 4.Cardiac tumors. In Crawford MH, DiMarco JP and Paulus WJ (eds): Cardiology. 3rd ed. Philadelphia, Elsevier Saunders, 2010, pp 1743–1751.Google Scholar
- 10.• Giusca S, Mereles D, Ochs A, Buss S, Andre F, Seitz S, et al. Incremental value of cardiac magnetic resonance for the evaluation of cardiac tumors in adults: experience of a high volume tertiary cardiology centre. Int J Card Imaging. 2017;33:879–88 This is a retrospective analysis of a large number of cardiac masses evaluated by cardiac MRI and shows superior mass identification as compared with echocardiography. CrossRefGoogle Scholar
- 13.Chan AT, Plodkowski AJ, Pun SC, Lakhman Y, Halpenny DF, Kim J, et al. Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer. J Cardiovasc Magn Reson. 2017;19:76.PubMedPubMedCentralCrossRefGoogle Scholar
- 16.Chan ATF, J. Perez Johnston, R. Plodkowski, A. Pollie, M. Moskowitz, C. Steingart, R. Weinsaft, J.W. Biologic and prognostic validation of delayed enhancement (DE-) CMR for cancer-associated cardiac masses - multimodality comparison to positron emission tomography (PET) [ABSTRACT]. Society for Cardiovascular Magnetic Resonance Scientific Sessions. 2018:22.Google Scholar
- 20.Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer I. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–53.PubMedCrossRefGoogle Scholar
- 22.Srichai MB, Junor C, Rodriguez LL, Stillman AE, Grimm RA, Lieber ML, Weaver JA, Smedira NG and White RD. Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation. Am Heart J. 2006;152:75-84.PubMedCrossRefGoogle Scholar
- 24.Weinsaft JW, Kim HW, Crowley AL, Klem I, Shenoy C, Van Assche L, Brosnan R, Shah DJ, Velazquez EJ, Parker M, Judd RM and Kim RJ. LV thrombus detection by routine echocardiography: insights into performance characteristics using delayed enhancement CMR. JACC Cardiovasc Imaging. 2011;4:702-12.PubMedGoogle Scholar
- 32.Centofanti P, Di Rosa E, Deorsola L, et al. Primary cardiac neoplasms: early and late results of surgical treatment in 91 patients. Ann Thorac Surg. 1999;68:1236–41.Google Scholar
- 35.McAllister H, Fenoglio J. Tumors of the cardiovascular system. In: Hartmannn W, Cowan W, editors. Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology; 1978. p. 1–20.Google Scholar
- 38.McCarthy PM, Piehler JM, Schaff HV, Pluth JR, Orszulak TA, Vidaillet HJ Jr, et al. The significance of multiple, recurrent, and “complex” cardiac myxomas. J Thorac Cardiovasc Surg. 1986;91:389–96.Google Scholar
- 44.Uzun O, Wilson DG, Vulanic GM, et al. Cardiac tumours in children. Orphanet J Rare Dis. 2007;2:11.Google Scholar
- 46.Chen TW, Loong HH, Srikanthan A, et al. Primary cardiac sarcomas: a multinational retrospective review. Cancer Med 2018; 1–7.Google Scholar
- 50.• Randhawa JS, Budd GT, Randhawa M, Ahluwalia M, Jia X, Daw H, et al. Primary cardiac sarcoma: 25-year Cleveland Clinic experience. Am J Clin Oncol. 2016;39(6):593–99. This is a retrospective review of 42 cases of primary cardiac sarcoma and described a benefit in patients who received multimodality therapy.PubMedCrossRefGoogle Scholar
- 52.•• Abu Saleh WK, Ramlawi B, Shapira OM, et al. Improved outcomes with the evolution of neoadjuvant chemotherapy approach to right heart sarcoma. Ann Thorac Surg. 2017;104(1):90–6. This is a single-center study of 133 primary cardiac sarcoma cases with a focus on the management of right-sided sarcomas. This study demonstrated a marked survival benefit with complete resection, leading to a recommendation for neoadjuvant therapy to increase the probability of achieving complete resection.PubMedCrossRefGoogle Scholar